BRAND: AirBuFo Forspiro
ACTIVE INGREDIENT: Budesonide/Formoterol
STRENGTH, PACK SIZE & GMS CODE:
AirBuFo Forspiro 160 microgram/4.5 microgram/dose inhalation powder, pre-dispensed x 2 inhalers, 60 doses – 29234
AirBuFo Forspiro is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting _2 adrenoceptor agonist) is appropriate:
– patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting B2 adrenoceptor agonists.
– patients already adequately controlled on both inhaled corticosteroids and long-acting B2 adrenoceptor agonists.
Chronic Obstructive Pulmonary Disease (COPD)
AirBuFo Forspiro is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy